Rich Pharmaceuticals, Inc. Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2018-03-31..
Gross margin
Overview →Financial period ending 2018-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2018-03-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 115.00K USD | |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2018-03-31 | (m) | $115.00K | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $0.00 | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $0.00 | (m) | (m) |
| 2013-09-30 | (m) | $0.00 | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.